Scisparc

Scisparc Gross Margin

The Gross Margin of Scisparc (SPRC) as of Nov 21, 2026 is 73.71 %. In the previous year, Gross Margin was 38.74 % — a change of 90.26% (higher).

Gross Margin

73.71 %

YoY

90.26%

Last updated:

Gross Margin of Scisparc is 2025 73.71 % . Gross Margin of Scisparc was 2024 38.74 % . It decreases by 90.26% higher compared to the previous year.

Scisparc's gross margin stands at 73.7%, down from 96.9% several years earlier.

The Scisparc Gross Margin history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

Gross Margin
Date
Gross Margin
Jan 1, 2018
82.46 USD
Jan 1, 2019
64.06 USD
Jan 1, 2020
70.18 USD
Jan 1, 2021
96.91 USD
Jan 1, 2022
76.10 USD
Jan 1, 2023
76.28 USD
Jan 1, 2024
38.74 USD
Jan 1, 2025
73.71 USD
The Scisparc Gross Margin history
YEARGross MarginYoY
73.71 %+90.26%
38.74 %-49.21%
76.28 %+0.24%
76.10 %-21.48%
96.91 %+38.09%
70.18 %+9.56%
64.06 %-22.32%
82.46 %-16.69%
98.97 %+11,131.80%
0.88 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Scisparc Stock analysis

What does Scisparc do? SciSparc Ltd develops cannabinoid-based pharmaceuticals including THX-110 for Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 for Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 for infectious diseases; and THX-160 for pain. The company monetizes through drug development programs targeting specific medical conditions, with pharmaceutical companies and research institutions as primary buyers of these development assets. The firm's revenue streams derive from licensing agreements and partnerships with biopharmaceutical entities seeking to advance cannabinoid-based therapies for unmet medical needs. SciSparc focuses on repurposing Dronabinol into multiple therapeutic applications, creating a diversified portfolio of drug candidates. Its products target neurological disorders, sleep disorders, and infectious diseases, appealing to healthcare providers and patients requiring innovative treatments. The company's business model relies on generating revenue through the sale of development-stage drug assets to larger pharmaceutical firms rather than direct patient sales. The firm's pipeline includes four distinct drug candidates, each addressing different medical conditions. THX-110 targets Tourette syndrome, Obstructive Sleep Apnea, and pain; THX-130 addresses Mild Cognitive Impairment and Traumatic Brain Injury; THX-150 targets infectious diseases; and THX-160 focuses on pain management. These assets are marketed to biopharmaceutical companies as potential additions to their therapeutic portfolios. Scisparc is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Scisparc stock

Gross Margin of Scisparc is 73.71 % in 2025.

Gross Margin of Scisparc changed from 38.74 % to 73.71 %, representing a 90.26% change. The value is higher than the previous year.

On Eulerpool you can find the complete historical development of Gross Margin Scisparc since 2006 – with annual values, charts, and detailed analysis.

Gross Margin measures the percentage of revenue remaining after COGS. Higher gross margins indicate more efficient production and stronger pricing power.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Gross Margin's Scisparc with sector peers and the industry average to assess whether it is attractive.

To evaluate Gross Margin's, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Gross Margin.

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Margins — Scisparc

All Key Metrics — Scisparc